MerckMRK
Merck’s June sales advance leaves the profit test unfinished
The cancer and vaccine maker generated positive operating cash, but its reported loss keeps attention on the economics behind the revenue.
NYSE · MRK
Merck · News
Quarterly results, stock moves and the business behind them.